WallStreetZenWallStreetZen

NASDAQ: YI
111 Inc Stock

$1.16+0.15 (+14.85%)
Updated Mar 28, 2024
YI Price
$1.16
Fair Value Price
N/A
Market Cap
$98.53M
52 Week Low
$0.98
52 Week High
$3.36
P/E
N/A
P/B
-1.24x
P/S
0.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.08B
Earnings
-$55.39M
Gross Margin
5.7%
Operating Margin
-2.49%
Profit Margin
-2.6%
Debt to Equity
-4.97
Operating Cash Flow
-$63M
Beta
0.73
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

YI Overview

111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services that include online consultation services and electronic prescription services to consumers. It offers prescription and over-the counter drugs, including western and traditional Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices comprising bandages and thermometers; and personal care products consisting of skin care, birth control, and sexual wellness products; and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Pharmacy, which include pharmacies and wholesalers; and data and supply chain integration services. As of December 31, 2021, it operated 14 offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan provinces. In addition, the company offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies and distributors, medical professionals, and insurance companies. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.

Zen Score

–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how YI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

YI's cash and short-term investments ($104.35M) cannot cover YI's cash burn for the next year ($139.09M), once increasing cash burn (123.91%) is accounted for
Interest Coverage Financials
YI's profit margin has increased (+0.5%) in the last year from (-3.1%) to (-2.6%), and is approaching profitability
Profit Margin Growth Financials
YI's short-term assets ($407.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more YI due diligence checks available for Premium users.

Be the first to know about important YI news, forecast changes, insider trades & much more!

YI News

Valuation

YI price to earnings (PE)

For valuing profitable companies with steady earnings
Company
0x
Industry
32.04x
Market
44.51x

YI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-1.24x
Industry
0.97x

YI's financial health

Profit margin

Revenue
$579.5M
Net Income
-$29.7M
Profit Margin
-5.1%
YI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
YI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$435.7M
Liabilities
$400.9M
Debt to equity
-4.97
YI's short-term assets ($407.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
YI's short-term assets ($407.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
YI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
YI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$27.8M
Investing
$8.4M
Financing
$246.5k
YI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

YI vs Pharmaceutical Retailer Stocks

TickerMarket Cap1d %P/EP/B
YI$98.53M+14.85%N/A-1.24x
PETS$101.29M-1.03%-16.52x0.89x
HITI$159.47M-1.46%-4.32x1.16x
BIMI$19.47M-7.64%-0.65x2.24x
MEDS$12.34M+7.23%-1.02x1.07x

111 Stock FAQ

What is 111's quote symbol?

(NASDAQ: YI) 111 trades on the NASDAQ under the ticker symbol YI. 111 stock quotes can also be displayed as NASDAQ: YI.

If you're new to stock investing, here's how to buy 111 stock.

What is the 52 week high and low for 111 (NASDAQ: YI)?

(NASDAQ: YI) 111's 52-week high was $3.36, and its 52-week low was $0.98. It is currently -65.48% from its 52-week high and 18.37% from its 52-week low.

How much is 111 stock worth today?

(NASDAQ: YI) 111 currently has 169,883,175 outstanding shares. With 111 stock trading at $1.16 per share, the total value of 111 stock (market capitalization) is $98.53M.

111 stock was originally listed at a price of $13.80 in Sep 12, 2018. If you had invested in 111 stock at $13.80, your return over the last 5 years would have been -91.59%, for an annualized return of -39.06% (not including any dividends or dividend reinvestments).

How much is 111's stock price per share?

(NASDAQ: YI) 111 stock price per share is $1.16 today (as of Mar 28, 2024).

What is 111's Market Cap?

(NASDAQ: YI) 111's market cap is $98.53M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

111's market cap is calculated by multiplying YI's current stock price of $1.16 by YI's total outstanding shares of 169,883,175.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.